Document is current
Any future updates will be listed below
-
Authors
Gardner, Wilf https://orcid.org/0000-0001-6211-9873
Sarrazin, David H. https://orcid.org/0000-0003-1326-3232
Balzinger, Martin
Marchese, Carole
Ragno, Axelle
Ramanathan, Chockalingam https://orcid.org/0000-0003-3668-4478
Veleanu, Maxime https://orcid.org/0000-0001-6760-3488
Vestring, Stefan https://orcid.org/0000-0001-9150-8712
Normann, Claus https://orcid.org/0000-0001-5693-8936
Bourgin, Patrice
Serchov, Tsvetan https://orcid.org/0000-0002-2234-2875
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SE 2666/2-1)
Deutsche Forschungsgemeinschaft (SE 2666/2-3)
Fondation pour la Recherche Médicale (AJE201912009450)
Université de Strasbourg (USIAS 2020-035)
- License Information
-
More Information
Article History
Received: 16 January 2025
Revised: 26 August 2025
Accepted: 16 September 2025
First Online: 29 September 2025
Competing interests
: CN received lecture fees and advisory board honoraria from Novartis, Johnson & Johnson, Boehringer und Precisis. All other authors declare that they have no competing interests to disclose.
: The Chronobiotron animal facility (Strasbourg) is registered for animal experimentation (Agreement A67-2018-38). All procedures were performed in accordance with the German animal protection law (TierSchG), FELASA ( ), the guide for care and use of laboratory animals of the national animal welfare body GV-SOLAS ) and the EU Directive 2010/63/EU for animal experiments and were approved by the local animal welfare committee of the University of Freiburg (X-20/06R, 35-9185.81/G-19/44 and G-15/117) and University of Strasbourg (CREMEAS, APAFIS n°2020042818477700).
